Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Dec 18, 2019
- First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 -
-
Dec 16, 2019
XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
-
Dec 9, 2019
Catherine Levitt and Charlotte Stanton named to key global and regional senior roles
-
Dec 5, 2019
Two exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research
-
Dec 2, 2019
Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation
-
Dec 2, 2019
- Companies to Initiate Phase 3 Trial to Support Global Registrations -
-
Nov 25, 2019
Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer
-
Oct 31, 2019
- Results were published online and in the October 31 print edition of the Journal -
-
-
Oct 28, 2019
- Four innovators awarded $200,000 in total grants and resources following live pitch event to a panel of judges that included celebrity entrepreneur Bill Rancic -
-
Oct 25, 2019
Approval follows accelerated assessment, orphan designation by European Medicines Agency
-
-
Oct 1, 2019
Financial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community
-
Sep 30, 2019
- Finalists will present their ideas during a live pitch event
-
Sep 28, 2019
- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -
-
Sep 24, 2019
- Astellas named Working Mother "100 Best Company" for fifth consecutive year -
-
Sep 20, 2019
If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)
-
-
Sep 18, 2019
- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -
-
Sep 16, 2019
- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -
-
Sep 11, 2019
Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
-
-
Aug 21, 2019
XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
-
-
-
Jul 16, 2019
-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-
-
Jul 10, 2019
Glinski to Oversee US Sales for XTANDI
-
Jun 3, 2019
-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-
-
May 30, 2019
- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -
-
May 20, 2019
-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -
-
-
May 5, 2019
- Data Presented at the American Urological Association 2019 Annual Meeting -
-
-
-
Apr 1, 2019
- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -
-
-
Mar 28, 2019
- Companies Plan to Submit Biologics License Application Later This Year -
-
Mar 26, 2019
- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -
-
-
-
Feb 20, 2019
Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making
-
Feb 11, 2019
Data to be presented at the 2019 Genitourinary Cancers Symposium
-
-
-
Dec 14, 2018
Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline
-
-
-
-
Nov 28, 2018
- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -
-
.svg)
